EC
Euclidean Capital Portfolio holdings
AUM
$306M
This Quarter Return
-25.01%
1 Year Return
+16.69%
3 Year Return
+17.66%
5 Year Return
–
10 Year Return
–
AUM
$299M
AUM Growth
+$299M
(-37%)
Cap. Flow
-$25.5M
Cap. Flow
% of AUM
-8.53%
Top 10 Holdings %
Top 10 Hldgs %
99.08%
Holding
14
New
4
Increased
–
Reduced
2
Closed
1
Top Buys
| 1 |
Beam Therapeutics
BEAM
|
$2.49M |
| 2 |
Vir Biotechnology
VIR
|
$1.33M |
| 3 |
Pinduoduo
PDD
|
$1.09M |
| 4 |
RUBY
Rubius Therapeutics, Inc
RUBY
|
$339K |
Top Sells
| 1 |
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
|
$17.2M |
| 2 |
Oric Pharmaceuticals
ORIC
|
$9.89M |
| 3 |
Revolution Medicines
RVMD
|
$3.7M |
Sector Composition
| 1 | Healthcare | 98.24% |
| 2 | Financials | 1.39% |
| 3 | Consumer Discretionary | 0.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
PMV Pharmaceuticals
PMVP
$74.2M
| $137M | 45.99% |
4,179,416
| – | – |
|
|
NGM
2
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $43.4M | 14.53% |
1,493,349
-590,253
| -28% | -$17.2M |
|
|
3
Oric Pharmaceuticals
ORIC
$994M
| $24.4M | 8.17% |
996,734
-403,701
| -29% | -$9.89M |
|
4
Alector
ALEC
$238M
| $19.8M | 6.61% |
980,894
| – | – |
|
5
Denali Therapeutics
DNLI
$2.23B
| $18.5M | 6.19% |
323,749
| – | – |
|
6
Foghorn Therapeutics
FHTX
$286M
| $16.6M | 5.56% |
1,261,261
| – | – |
|
7
RAPT Therapeutics
RAPT
$188M
| $16.3M | 5.47% |
735,801
| – | – |
|
|
CNST
8
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $13M | 4.34% |
554,325
| – | – |
|
9
First Financial Bancorp
FFBC
$2.51B
| $4.17M | 1.39% |
173,576
| – | – |
|
|
10
Beam Therapeutics
BEAM
$1.66B
| $2.49M | 0.83% |
+31,131
| New | +$2.49M |
|
|
11
Vir Biotechnology
VIR
$686M
| $1.33M | 0.44% |
+25,864
| New | +$1.33M |
|
|
12
Pinduoduo
PDD
$171B
| $1.09M | 0.37% |
+8,174
| New | +$1.09M |
|
|
RUBY
13
DELISTED
Rubius Therapeutics, Inc
RUBY
| $339K | 0.11% |
+12,791
| New | +$339K |
|
|
14
Revolution Medicines
RVMD
$7.1B
| – | – |
-93,436
| Closed | -$3.7M |
|